A detailed history of Squarepoint Ops LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Squarepoint Ops LLC holds 64,808 shares of ABUS stock, worth $206,737. This represents 0.0% of its overall portfolio holdings.

Number of Shares
64,808
Previous 1,445,000 95.52%
Holding current value
$206,737
Previous $4.47 Million 94.42%
% of portfolio
0.0%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.12 - $4.56 $202,200 - $295,524
64,808 New
64,808 $249,000
Q4 2022

Feb 14, 2023

BUY
$1.91 - $2.85 $26,071 - $38,902
13,650 New
13,650 $31,000
Q1 2022

May 16, 2022

SELL
$2.42 - $3.98 $96,833 - $159,255
-40,014 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $124,443 - $184,464
40,014 New
40,014 $156,000
Q2 2021

Aug 16, 2021

SELL
$2.5 - $3.51 $74,700 - $104,878
-29,880 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$3.14 - $4.84 $93,823 - $144,619
29,880 New
29,880 $100,000
Q3 2020

Nov 16, 2020

SELL
$1.75 - $6.2 $563,893 - $2 Million
-322,225 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$0.91 - $2.36 $254,783 - $660,757
279,982 Added 662.79%
322,225 $586,000
Q1 2020

May 15, 2020

BUY
$1.01 - $3.42 $42,665 - $144,471
42,243 New
42,243 $43,000
Q3 2019

Nov 14, 2019

SELL
$1.34 - $2.4 $88,236 - $158,035
-65,848 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$1.46 - $4.44 $96,138 - $292,365
65,848 New
65,848 $137,000
Q2 2018

Aug 14, 2018

SELL
$5.0 - $7.35 $66,500 - $97,755
-13,300 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$4.4 - $6.05 $1,320 - $1,815
-300 Reduced 2.21%
13,300 $67,000
Q4 2017

Feb 14, 2018

BUY
$4.45 - $7.7 $14,685 - $25,410
3,300 Added 32.04%
13,600 $69,000
Q3 2017

Nov 14, 2017

BUY
$3.4 - $7.0 $35,020 - $72,100
10,300
10,300 $64,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $478M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.